Abstract
Histone deacetylase inhibitors (HDACi) are a new generation of epigenetic modulators class of drugs but with low efficacy as cancer monotherapy, due to the upregulation of several tumor progressive genes. Combination of these drugs with various PKC inhibitors such as Tamoxifen showed increased efficiency for the treatment by inhibiting cell viability by nearly 50%. Panobinostat (LBH‐589) is a novel HDACi that induces apoptosis via multiple pathways in tumor cells. This study investigated the effect of Panobinostat alone and in combination with Tamoxifen on U‐87 Glioblastoma cell viability and subsequent morphological changes. Treatment with Panobinostat at IC50 showed 80% decrease in cell viability at 72 hours. Combination therapy of Panobinostat and Tamoxifen showed no significant decrease in cell viability as compared to a single therapy with Panobinostat. This was also observed morphologically. Our results report Panobinostat as a potential anticancer agent in glioblastoma. Further studies will investigate cancer progression in glioblastoma cell line.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
